Literature DB >> 18988205

Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.

Sebastian Polak1, Barbara Wiśniowska, Jerzy Brandys.   

Abstract

The assessment of the torsadogenic potency of a new chemical entity is a crucial issue during lead optimization and the drug development process. It is required by the regulatory agencies during the registration process. In recent years, there has been a considerable interest in developing in silico models, which allow prediction of drug-hERG channel interaction at the early stage of a drug development process. The main mechanism underlying an acquired QT syndrome and a potentially fatal arrhythmia called torsades de pointes is the inhibition of potassium channel encoded by hERG (the human ether-a-go-go-related gene). The concentration producing half-maximal block of the hERG potassium current (IC(50)) is a surrogate marker for proarrhythmic properties of compounds and is considered a test for cardiac safety of drugs or drug candidates. The IC(50) values, obtained from data collected during electrophysiological studies, are highly dependent on experimental conditions (i.e. model, temperature, voltage protocol). For the in silico models' quality and performance, the data quality and consistency is a crucial issue. Therefore the main objective of our work was to collect and assess the hERG IC(50) data available in accessible scientific literature to provide a high-quality data set for further studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18988205     DOI: 10.1002/jat.1395

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  26 in total

1.  Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2.

Authors:  G Eichenbaum; M K Pugsley; D J Gallacher; R Towart; G McIntyre; U Shukla; J M Davenport; H R Lu; J Rohrbacher; V Hillsamer
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 2.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

3.  Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.

Authors:  Yayu Tan; Yadong Chen; Qidong You; Haopeng Sun; Manhua Li
Journal:  J Mol Model       Date:  2011-06-10       Impact factor: 1.810

4.  Compilation and physicochemical classification analysis of a diverse hERG inhibition database.

Authors:  Remigijus Didziapetris; Kiril Lanevskij
Journal:  J Comput Aided Mol Des       Date:  2016-10-25       Impact factor: 3.686

5.  ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage.

Authors:  Sichao Wang; Youyong Li; Junmei Wang; Lei Chen; Liling Zhang; Huidong Yu; Tingjun Hou
Journal:  Mol Pharm       Date:  2012-03-16       Impact factor: 4.939

6.  Deep Learning-Based Prediction of Drug-Induced Cardiotoxicity.

Authors:  Chuipu Cai; Pengfei Guo; Yadi Zhou; Jingwei Zhou; Qi Wang; Fengxue Zhang; Jiansong Fang; Feixiong Cheng
Journal:  J Chem Inf Model       Date:  2019-02-15       Impact factor: 4.956

7.  In silico prediction of hERG potassium channel blockage by chemical category approaches.

Authors:  Chen Zhang; Yuan Zhou; Shikai Gu; Zengrui Wu; Wenjie Wu; Changming Liu; Kaidong Wang; Guixia Liu; Weihua Li; Philip W Lee; Yun Tang
Journal:  Toxicol Res (Camb)       Date:  2016-01-14       Impact factor: 3.524

Review 8.  Evolution of strategies to improve preclinical cardiac safety testing.

Authors:  Gary Gintant; Philip T Sager; Norman Stockbridge
Journal:  Nat Rev Drug Discov       Date:  2016-02-19       Impact factor: 84.694

9.  Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics and risk factors.

Authors:  I Gueta; R Loebstein; N Markovits; Y Kamari; H Halkin; G Livni; H Yarden-Bilavsky
Journal:  Eur J Clin Pharmacol       Date:  2017-06-17       Impact factor: 2.953

10.  Tuning HERG out: antitarget QSAR models for drug development.

Authors:  Rodolpho C Braga; Vinicius M Alves; Meryck F B Silva; Eugene Muratov; Denis Fourches; Alexander Tropsha; Carolina H Andrade
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.